Cited by 535SARS-CoV-2 and COVID-19 Researchvaccines and immunoinformatics approachesAnimal Virus Infections Studies

The DOI matches its Crossref record; 89 of the 90 references it cites were found in a registry or an index, and 1 are not checked yet.

Structural basis of SARS-CoV-2 Omicron immune evasion and receptor engagement

Open access

McCallum, Matthew, Czudnochowski, Nadine, Rosen, Laura E., Zepeda, Samantha K., Bowen, John E., Walls, Alexandra C., Hauser, Kevin, Joshi, Anshu, Stewart, Cameron, Dillen, Josh R., Powell, Abigail E., Croll, Tristan I., Nix, Jay, Virgin, Herbert W., Corti, Davide, Snell, Gyorgy, Veesler, David·2022·Science

DOI 10.1126/science.abn8652PMC PMC9427005

Published version of a preprint

Open this paper in CoChat — free account

Abstract

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron variant of concern evades antibody-mediated immunity that comes from vaccination or infection with earlier variants due to accumulation of numerous spike mutations. To understand the Omicron antigenic shift, we determined cryo–electron microscopy and x-ray crystal structures of the spike protein and the receptor-binding domain bound to the broadly neutralizing sarbecovirus monoclonal antibody (mAb) S309 (the parent mAb of sotrovimab) and to the human ACE2 receptor. We provide a blueprint for understanding the marked reduction of binding of other therapeutic mAbs that leads to dampened neutralizing activity. Remodeling of interactions between the Omicron receptor-binding domain and human ACE2 likely explains the enhanced affinity for the host receptor relative to the ancestral virus.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1126/science.abn8652

Cites

89 of 90 references verified0 citation errors · 0 not checkable

Statistics

Fig. 1. CryoEM structure of the SARS-CoV-2 Omicron S trimer reveals a remodeling of the NTD antigenic supersite. (A) Surface rendering in two orthogonal orientations of the Omicron S trimer with one open RBD bound to the S309 (grey) and S2L20 (green) Fabs shown as ribbons. The three S protomers are colored light blue, pink or gold. N-linked glycans are shown as dark blue surfaces. (B) Ribbon diagrams in two orthogonal orientations of the S trimer with one open RBD with Omicron residues mutated relative to Wuhan-Hu-1 shown as red spheres (except D614G which is not shown). (C) The S2L20-bound Omicron NTD with mutated, deleted, or inserted residues rendered or indicated as red spheres. Segments with notable structural changes are shown in orange and labeled. (D) Zoomed-in view of the Omicron NTD antigenic supersite overlaid with the S2X333 Fab (used here as an example of prototypical NTD neutralizing mAb (22)) highlighting the binding incompatibility; the modeled clash between S2X333 W106 and NTD G142D is indicated with an asterisk.CC BY · PubMed Central

Fig. 2. SARS-CoV-2 Omicron S mutations outside the NTD and RBD. Ribbon diagram showing a cross-section of the Omicron S glycoprotein (the location of this slice on the S trimer is indicated on the left). Mutated residues T547K, N764K, N856K, N969K, and L981F are shown as red spheres whereas the residues they contact are shown as spheres colored as the protomer they belong to. Black asterisks show the position of residues involved in the prefusion-stabilizing 2P mutations (K986P and V987P) used in all three vaccines deployed in the US. The three S protomers are colored light blue, pink or gold. N-linked glycans are shown as dark blue surfaces.CC BY · PubMed Central

Fig. 3. SARS-CoV-2 Omicron RBD mutations promote escape from a panel of clinical mAbs. (A, RBD antigenic map as determined elsewhere (13). (B) Ribbon diagram of the RBD crystal structure with residue mutated relative to the Wuhan-Hu-1 RBD shown as red spheres. The N343 glycan is rendered as blue spheres. (C to J) Zoomed-in view of the Omicron RBD (blue) superimposed on structures of clinical mAbs (grey) highlighting (black circles) selected residues that interfere with the mAbs: (C) REGN10933, (D) REGN10987, (E) COV2-2196, (F) COV2-2130, (G) LY-CoV555, (H) LY-CoV16, (I) CT-P59, and (J) S309 which does not clash with G339D. Panels A-I were rendered with the crystal structure whereas panel J was generated using the cryoEM model. Binding of the Wuhan-Hu-1 (gray line) or Omicron (red line) RBD to the corresponding mAb was evaluated using surface plasmon resonance (single-cycle kinetics) and is shown underneath each structural superimposition. White and gray stripes are association and dissociation phases, respectively. The black line is a fit to a kinetic model. The decrease in affinity between Wuhan-Hu-1 and Omicron binding is indicated in red. Results are consistent with IgG binding to S ectodomains (fig. S3).CC BY · PubMed Central

Fig. 4. Molecular basis of human ACE2 recognition by the SARS-CoV-2 Omicron RBD. (A) Ribbon diagram of the crystal structure of the Omicron RBD in complex with the ACE2 ectodomain. The S309 and S304 Fab fragments are not shown for clarity. (B to E) Zoomed-in views of the RBD/ACE2 interface highlighting modulation of interactions due to introduction of the N501Y (B), K417N (C), Q493R/Q498R (D) and S477N (E) residue substitutions.CC BY · PubMed Central

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

UCSF Chimera—A visualization system for exploratory research and analysis
Pettersen, E. F., Goddard, T. D., Huang, C. C., Couch, G. S., Greenblatt, D. M., Meng, E. C., & Ferrin, T. E. (2004) · Journal of Computational Chemistry · doi:10.1002/jcc.20084 · Cited by 45,882
Features and development of Coot
Emsley, P., Lohkamp, B., Scott, W. G., & Cowtan, K. (2010) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444910007493 · Cited by 29,915
Phaser crystallographic software
McCoy, A. J., Grosse-Kunstleve, R. W., Adams, P. D., Winn, M. D., Storoni, L. C., & Read, R. J. (2007) · Journal of Applied Crystallography · doi:10.1107/s0021889807021206 · Cited by 20,612
MolProbity : all-atom structure validation for macromolecular crystallography
Chen, V. B., Arendall, W. B., Headd, J. J., Keedy, D. A., Immormino, R. M., Kapral, G. J., Murray, L. W., Richardson, J. S., & Richardson, D. C. (2010) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444909042073 · Cited by 14,115
cryoSPARC: algorithms for rapid unsupervised cryo-EM structure determination
Punjani, A., Rubinstein, J. L., Fleet, D. J., & Brubaker, M. A. (2017) · Nature Methods · doi:10.1038/nmeth.4169 · Cited by 11,626
Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation
Wrapp, D., Wang, N., Corbett, K. S., Goldsmith, J. A., Hsieh, C.-L., Abiona, O., Graham, B. S., & McLellan, J. S. (2020) · Science · doi:10.1126/science.abb2507 · Cited by 8,897
Structure, function and antigenicity of the SARS-CoV-2 spike glycoprotein
Walls, A. C., Park, Y.-J., Tortorici, M. A., Wall, A., McGuire, A. T., & Veesler, D. (2020) · doi:10.1101/2020.02.19.956581 · Cited by 8,586 · cited 1×
“However, the region comprising residues 366 to 375, which harbors the S371L/S373P/S375F substitutions, deviates markedly from the conformation observed for the Wuhan-Hu-1 RBD, irrespective of the presence of bound linoleic acid ( 4 , 42 , 43 ).”
Self-citation
REFMAC 5 for the refinement of macromolecular crystal structures
Murshudov, G. N., Skubák, P., Lebedev, A. A., Pannu, N. S., Steiner, R. A., Nicholls, R. A., Winn, M., Long, F., & Vagin, A. A. (2011) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444911001314 · Cited by 8,415
Macromolecular structure determination using X-rays, neutrons and electrons: recent developments in Phenix
Liebschner, D., Afonine, P. V., Baker, M. L., Bunkóczi, G., Chen, V. B., Croll, T. I., Hintze, B., Hung, L.-W., Jain, S., McCoy, A. J., et al. (2019) · Acta Crystallographica Section D Structural Biology · doi:10.1107/s2059798319011471 · Cited by 7,953
Self-citation
Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor
Lan, J., Ge, J., Yu, J., Shan, S., Zhou, H., Fan, S., Zhang, Q., Shi, X., Wang, Q., Zhang, L., et al. (2020) · Nature · doi:10.1038/s41586-020-2180-5 · Cited by 5,983 · cited 2×
“The Omicron RBD is structurally similar to the Wuhan-Hu-1 RBD and both structures can be superimposed with an r.m.s.d. of 0.8Å over 183 aligned C ɑ residues (as compared to PDB 6m0j ( 42 )).”
RELION: Implementation of a Bayesian approach to cryo-EM structure determination
Scheres, S. H. W. (2012) · Journal of Structural Biology · doi:10.1016/j.jsb.2012.09.006 · Cited by 5,446
UCSF ChimeraX: Meeting modern challenges in visualization and analysis
Goddard, T. D., Huang, C. C., Meng, E. C., Pettersen, E. F., Couch, G. S., Morris, J. H., & Ferrin, T. E. (2018) · Protein Science · doi:10.1002/pro.3235 · Cited by 5,267
New tools for automated high-resolution cryo-EM structure determination in RELION-3
Zivanov, J., Nakane, T., Forsberg, B., Kimanius, D., Hagen, W., Lindahl, E., & Scheres, S. (2018) · eLife · doi:10.7554/elife.42166 · Cited by 4,377
Optimal determination of particle orientation, absolute hand, and contrast loss in single-particle electron cryomicroscopy
Rosenthal, P. B., & Henderson, R. (2003) · Journal of Molecular Biology · doi:10.1016/j.jmb.2003.07.013 · Cited by 2,416
Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7
Wang, P., Nair, M. S., Liu, L., Iketani, S., Luo, Y., Guo, Y., Wang, M., Yu, J., Zhang, B., Kwong, P. D., et al. (2021) · Nature · doi:10.1038/s41586-021-03398-2 · Cited by 2,312 · cited 2×
“S4, and table S3) and neutralization of single mutant S pseudoviruses ( 9 , 40 , 41 ).”
Omicron escapes the majority of existing SARS-CoV-2 neutralizing antibodies
Cao, Y., Wang, J., Jian, F., Xiao, T., Song, W., Yisimayi, A., Huang, W., Li, Q., Wang, P., An, R., et al. (2022) · Nature · doi:10.1038/s41586-021-04385-3 · Cited by 2,006
ISOLDE : a physically realistic environment for model building into low-resolution electron-density maps
Croll, T. I. (2018) · Acta Crystallographica Section D Structural Biology · doi:10.1107/s2059798318002425 · Cited by 1,966
Self-citation
Deep Mutational Scanning of SARS-CoV-2 Receptor Binding Domain Reveals Constraints on Folding and ACE2 Binding
Starr, T. N., Greaney, A. J., Hilton, S. K., Ellis, D., Crawford, K. H. D., Dingens, A. S., Navarro, M. J., Bowen, J. E., Tortorici, M. A., Walls, A. C., et al. (2020) · Cell · doi:10.1016/j.cell.2020.08.012 · Cited by 1,956 · cited 2×
“R346K does not affect S309 whether in isolation or in the context of the full constellation of Omicron mutations illustrating that mAbs targeting antigenic site IV can be differently affected by Omicron ( 7 , 9 , 46 ).”
Self-citation
Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody
Pinto, D., Park, Y.-J., Beltramello, M., Walls, A. C., Tortorici, M. A., Bianchi, S., Jaconi, S., Culap, K., Zatta, F., De Marco, A., et al. (2020) · Nature · doi:10.1038/s41586-020-2349-y · Cited by 1,885 · cited 3×
“…C135 was identified from a SARS-CoV-2 convalescent donor ( 25 ), S309 was isolated from a subject who recovered from a SARS-CoV infection in 2003 ( 12 ); the latter strategy increased the likelihood of finding mAbs recognizing epitopes that are mutationally constrained throughout sarbecovirus…”
Self-citation
Automated molecular microscopy: The new Leginon system
Suloway, C. J. M., Pulokas, J., Fellmann, D., Cheng, A., Guerra, F., Quispe, J. D., Stagg, S. M., Potter, C. S., & Carragher, B. O. (2005) · Journal of Structural Biology · doi:10.1016/j.jsb.2005.03.010 · Cited by 1,695
Rapid epidemic expansion of the SARS-CoV-2 Omicron variant in southern Africa
Viana, R. P. E. S., Moyo, S. M., Amoako, D. G., Tegally, H., Scheepers, C., Althaus, C. L., Anyaneji, U. J., Bester, P. A., Boni, M. F., Chand, M., et al. (2022) · Nature · doi:10.1038/s41586-022-04411-y · Cited by 1,678
SARS-CoV-2 neutralizing antibody structures inform therapeutic strategies
Barnes, C. O., Jette, C. A., Abernathy, M. E., Dam, K.-M. A., Esswein, S. R., Gristick, H. B., Malyutin, A. G., Sharaf, N. G., Huey-Tubman, K. E., Lee, Y. E., et al. (2020) · Nature · doi:10.1038/s41586-020-2852-1 · Cited by 1,599
Non-uniform refinement: adaptive regularization improves single-particle cryo-EM reconstruction
Punjani, A., Zhang, H., & Fleet, D. J. (2020) · Nature Methods · doi:10.1038/s41592-020-00990-8 · Cited by 1,559
Considerable escape of SARS-CoV-2 Omicron to antibody neutralization
Planas, D., Saunders, N., Maes, P., Guivel-Benhassine, F., Planchais, C., Buchrieser, J., Bolland, W.-H., Porrot, F., Staropoli, I., Lemoine, F., et al. (2022) · Nature · doi:10.1038/s41586-021-04389-z · Cited by 1,514
Mapping Neutralizing and Immunodominant Sites on the SARS-CoV-2 Spike Receptor-Binding Domain by Structure-Guided High-Resolution Serology
Piccoli, L., Park, Y.-J., Tortorici, M. A., Czudnochowski, N., Walls, A. C., Beltramello, M., Silacci-Fregni, C., Pinto, D., Rosen, L. E., Bowen, J. E., et al. (2020) · Cell · doi:10.1016/j.cell.2020.09.037 · Cited by 1,395 · cited 2×
“The K417N, G446S, S477N, T478K, E484A, Q493R, G496S, Q498R, N501Y and Y505H mutations are part of antigenic site I, which is immunodominant in previous variants ( 13 , 24 ).”
Self-citation
Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants
Weisblum, Y., Schmidt, F., Zhang, F., DaSilva, J., Poston, D., Lorenzi, J. C., Muecksch, F., Rutkowska, M., Hoffmann, H.-H., Michailidis, E., et al. (2020) · eLife · doi:10.7554/elife.61312 · Cited by 1,308 · cited 1×
“%) harbor the R346K substitution which in conjunction with N440K (present in the main haplotype) leads to escape from C135 mAb-mediated neutralization ( 25 , 51 ).”
Structure-based design of prefusion-stabilized SARS-CoV-2 spikes
Hsieh, C.-L., Goldsmith, J. A., Schaub, J. M., DiVenere, A. M., Kuo, H.-C., Javanmardi, K., Le, K. C., Wrapp, D., Lee, A. G., Liu, Y., et al. (2020) · Science · doi:10.1126/science.abd0826 · Cited by 1,303
Real-time cryo-electron microscopy data preprocessing with Warp
Tegunov, D., & Cramer, P. (2019) · Nature Methods · doi:10.1038/s41592-019-0580-y · Cited by 1,292
Striking antibody evasion manifested by the Omicron variant of SARS-CoV-2
Liu, L., Iketani, S., Guo, Y., Chan, J. F.-W., Wang, M., Liu, L., Luo, Y., Chu, H., Huang, Y., Nair, M. S., et al. (2022) · Nature · doi:10.1038/s41586-021-04388-0 · Cited by 1,290 · cited 9×
“Furthermore, S477N and Q493R have been shown to dampen binding of and neutralization mediated by LY-CoV16 ( 9 , 41 ).”
Influential
Studies in humanized mice and convalescent humans yield a SARS-CoV-2 antibody cocktail
Hansen, J., Baum, A., Pascal, K. E., Russo, V., Giordano, S., Wloga, E., Fulton, B. O., Yan, Y., Koon, K., Patel, K., et al. (2020) · Science · doi:10.1126/science.abd0827 · Cited by 1,210
SARS-CoV-2 Omicron spike mediated immune escape and tropism shift
Meng, B., Ferreira, I. A. T. M., Abdullahi, A., Goonawardane, N., Saito, A., Kimura, I., Yamasoba, D., Gerba, P. P., Fatihi, S., Rathore, S., et al. (2021) · doi:10.1101/2021.12.17.473248 · Cited by 1,147
Self-citation
Altered TMPRSS2 usage by SARS-CoV-2 Omicron impacts infectivity and fusogenicity
Meng, B., Abdullahi, A., Ferreira, I. A. T. M., Goonawardane, N., Saito, A., Kimura, I., Yamasoba, D., Gerber, P. P., Fatihi, S., Rathore, S., et al. (2022) · Nature · doi:10.1038/s41586-022-04474-x · Cited by 1,146
Self-citation
Broadly neutralizing antibodies overcome SARS-CoV-2 Omicron antigenic shift
Cameroni, E., Bowen, J. E., Rosen, L. E., Saliba, C., Zepeda, S. K., Culap, K., Pinto, D., VanBlargan, L. A., Marco, A. D., di Iulio, J., et al. (2021) · Nature · doi:10.1038/s41586-021-04386-2 · Cited by 1,070
Self-citation
Potently neutralizing and protective human antibodies against SARS-CoV-2
Zost, S. J., Gilchuk, P., Case, J. B., Binshtein, E., Chen, R. E., Nkolola, J. P., Schäfer, A., Reidy, J. X., Trivette, A., Nargi, R. S., et al. (2020) · Nature · doi:10.1038/s41586-020-2548-6 · Cited by 1,041
High-resolution noise substitution to measure overfitting and validate resolution in 3D structure determination by single particle electron cryomicroscopy
Chen, S., McMullan, G., Faruqi, A. R., Murshudov, G. N., Short, J. M., Scheres, S. H. W., & Henderson, R. A. (2013) · Ultramicroscopy · doi:10.1016/j.ultramic.2013.06.004 · Cited by 1,005
N-terminal domain antigenic mapping reveals a site of vulnerability for SARS-CoV-2
McCallum, M., De Marco, A., Lempp, F. A., Tortorici, M. A., Pinto, D., Walls, A. C., Beltramello, M., Chen, A., Liu, Z., Zatta, F., et al. (2021) · Cell · doi:10.1016/j.cell.2021.03.028 · Cited by 901 · cited 2×
“1D) ( 2 , 22 ).”
Self-citation
The Omicron variant is highly resistant against antibody-mediated neutralization: Implications for control of the COVID-19 pandemic
Hoffmann, M., Krüger, N., Schulz, S., Cossmann, A., Rocha, C., Kempf, A., Nehlmeier, I., Graichen, L., Moldenhauer, A.-S., Winkler, M. S., et al. (2022) · Cell · doi:10.1016/j.cell.2021.12.032 · Cited by 889 · cited 1×
“S7A) and can utilize mouse ACE2 as an entry receptor for S-mediated entry ( 7 , 49 ).”
The Omicron variant is highly resistant against antibody-mediated neutralization – implications for control of the COVID-19 pandemic
(2021) · doi:10.1101/2021.12.12.472286 · Cited by 889
EMRinger: side chain–directed model and map validation for 3D cryo-electron microscopy
Barad, B. A., Echols, N., Wang, R. Y.-R., Cheng, Y., DiMaio, F., Adams, P. D., & Fraser, J. S. (2015) · Nature Methods · doi:10.1038/nmeth.3541 · Cited by 886
A Bayesian approach to beam-induced motion correction in cryo-EM single-particle analysis
Zivanov, J., Nakane, T., & Scheres, S. H. W. (2018) · IUCrJ · doi:10.1107/s205225251801463x · Cited by 879
Structures of Human Antibodies Bound to SARS-CoV-2 Spike Reveal Common Epitopes and Recurrent Features of Antibodies
Barnes, C. O., West, A. P., Huey-Tubman, K. E., Hoffmann, M. A. G., Sharaf, N. G., Hoffman, P. R., Koranda, N., Gristick, H. B., Gaebler, C., Muecksch, F., et al. (2020) · Cell · doi:10.1016/j.cell.2020.06.025 · Cited by 795
Structural insights into coronavirus entry
(2019) · Advances in Virus Research · doi:10.1016/bs.aivir.2019.08.002 · Cited by 769 · cited 1×
“2) ( 16 , 17 ).”
Self-citation
Prospective mapping of viral mutations that escape antibodies used to treat COVID-19
Starr, T. N., Greaney, A. J., Addetia, A., Hannon, W. W., Choudhary, M. C., Dingens, A. S., Li, J. Z., & Bloom, J. D. (2021) · Science · doi:10.1126/science.abf9302 · Cited by 743 · cited 2×
“Furthermore, S477N and Q493R have been shown to dampen binding of and neutralization mediated by LY-CoV16 ( 9 , 41 ).”
SARS-CoV-2 B.1.1.7 sensitivity to mRNA vaccine-elicited, convalescent and monoclonal antibodies
Collier, D. A., De Marco, A., Ferreira, I. A. T. M., Meng, B., Datir, R., Walls, A. C., Kemp S, S. A., Bassi, J., Pinto, D., Fregni, C. S., et al. (2021) · doi:10.1101/2021.01.19.21249840 · Cited by 729
Self-citation
Sensitivity of SARS-CoV-2 B.1.1.7 to mRNA vaccine-elicited antibodies
Collier, D. A., De Marco, A., Ferreira, I. A. T. M., Meng, B., Datir, R. P., Walls, A. C., Kemp, S. A., Bassi, J., Pinto, D., Silacci-Fregni, C., et al. (2021) · Nature · doi:10.1038/s41586-021-03412-7 · Cited by 728
Self-citation
An infectious SARS-CoV-2 B.1.1.529 Omicron virus escapes neutralization by therapeutic monoclonal antibodies
VanBlargan, L. A., Errico, J. M., Halfmann, P., Zost, S. J., Crowe, J. E., Purcell, L. A., Kawaoka, Y., Corti, D., Fremont, D. H., & Diamond, M. (2022) · Nature Medicine · doi:10.1038/s41591-021-01678-y · Cited by 690
Self-citation
Attenuated fusogenicity and pathogenicity of SARS-CoV-2 Omicron variant
Suzuki, R., Yamasoba, D., Kimura, I., Wang, L., Kishimoto, M., Ito, J., Morioka, Y., Nao, N., Nasser, H., Uriu, K., et al. (2022) · Nature · doi:10.1038/s41586-022-04462-1 · Cited by 662 · cited 1×
“Putatively enhanced interactions between the S 1 and S 2 subunits in Omicron S along with pre-fusion stabilization, and altered processing at the S 1 /S 2 cleavage site due to the N679K and P681H mutations, might reduce S 1 shedding, consistent with recent studies ( 18 – 20 ).”
A Mouse-Adapted SARS-CoV-2 Induces Acute Lung Injury and Mortality in Standard Laboratory Mice
Leist, S. R., Dinnon, K. H., Schäfer, A., Tse, L. V., Okuda, K., Hou, Y. J., West, A., Edwards, C. E., Sanders, W., Fritch, E. J., et al. (2020) · Cell · doi:10.1016/j.cell.2020.09.050 · Cited by 613 · cited 1×
“These findings concur with the emergence and fixation of the Q493K RBD mutation upon serial passaging in mice to yield a mouse-adapted virus designated SARS-CoV-2 MA10 ( 50 ).”
Circulating SARS-CoV-2 spike N439K variants maintain fitness while evading antibody-mediated immunity
Thomson, E. C., Rosen, L. E., Shepherd, J. G., Spreafico, R., da Silva Filipe, A., Wojcechowskyj, J. A., Davis, C., Piccoli, L., Pascall, D. J., Dillen, J., et al. (2021) · Cell · doi:10.1016/j.cell.2021.01.037 · Cited by 606
Self-citation
mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection
Stamatatos, L., Czartoski, J., Wan, Y.-H., Homad, L. J., Rubin, V., Glantz, H., Neradilek, M., Seydoux, E., Jennewein, M. F., MacCamy, A. J., et al. (2021) · Science · doi:10.1126/science.abg9175 · Cited by 557 · cited 1×
“The RBD is the main target of plasma neutralizing activity in convalescent and vaccinated individuals and comprises several antigenic sites recognized by neutralizing Abs with a range of neutralization potencies and breadth ( 12 , 13 , 21 , 23 – 36 ) (Fig.”
Cryo-electron microscopy structure of a coronavirus spike glycoprotein trimer
Walls, A. C., Tortorici, M. A., Bosch, B., Frenz, B., Rottier, P. J. M., DiMaio, F., Rey, F. A., & Veesler, D. (2016) · Nature · doi:10.1038/nature16988 · Cited by 533 · cited 1×
“2) ( 16 , 17 ).”
Self-citation
Elicitation of Potent Neutralizing Antibody Responses by Designed Protein Nanoparticle Vaccines for SARS-CoV-2
Walls, A. C., Fiala, B., Schäfer, A., Wrenn, S., Pham, M. N., Murphy, M., Tse, L. V., Shehata, L., O’Connor, M. A., Chen, C., et al. (2020) · Cell · doi:10.1016/j.cell.2020.10.043 · Cited by 532
Self-citation
Broad neutralization of SARS-related viruses by human monoclonal antibodies
Wec, A. Z., Wrapp, D., Herbert, A. S., Maurer, D. P., Haslwanter, D., Sakharkar, M., Jangra, R. K., Dieterle, M. E., Lilov, A., Huang, D., et al. (2020) · Science · doi:10.1126/science.abc7424 · Cited by 526
Potent SARS-CoV-2 neutralizing antibodies directed against spike N-terminal domain target a single supersite
Cerutti, G., Guo, Y., Zhou, T., Gorman, J., Lee, M., Rapp, M., Reddem, E. R., Yu, J., Bahna, F., Bimela, J., et al. (2021) · Cell Host & Microbe · doi:10.1016/j.chom.2021.03.005 · Cited by 519
SARS-CoV-2 RBD antibodies that maximize breadth and resistance to escape
Starr, T. N., Czudnochowski, N., Liu, Z., Zatta, F., Park, Y., Addetia, A., Pinto, D., Beltramello, M., Hernandez, P., Greaney, A. J., et al. (2021) · Nature · doi:10.1038/s41586-021-03807-6 · Cited by 503
Self-citation
Complete map of SARS-CoV-2 RBD mutations that escape the monoclonal antibody LY-CoV555 and its cocktail with LY-CoV016
Starr, T. N., Greaney, A. J., Dingens, A. S., & Bloom, J. D. (2021) · Cell Reports Medicine · doi:10.1016/j.xcrm.2021.100255 · Cited by 470
Automated structure refinement of macromolecular assemblies from cryo-EM maps using Rosetta
Wang, R. Y.-R., Song, Y., Barad, B. A., Cheng, Y., Fraser, J. S., & DiMaio, F. (2016) · eLife · doi:10.7554/elife.17219 · Cited by 457
Free fatty acid binding pocket in the locked structure of SARS-CoV-2 spike protein
Toelzer, C., Gupta, K., Yadav, S. K. N., Borucu, U., Davidson, A. D., Williamson, M. K., Shoemark, D. K., Garzoni, F., Staufer, O., Milligan, R., et al. (2020) · Science · doi:10.1126/science.abd3255 · Cited by 427 · cited 1×
“However, the region comprising residues 366 to 375, which harbors the S371L/S373P/S375F substitutions, deviates markedly from the conformation observed for the Wuhan-Hu-1 RBD, irrespective of the presence of bound linoleic acid ( 4 , 42 , 43 ).”
SARS-CoV-2 immune evasion by the B.1.427/B.1.429 variant of concern
McCallum, M., Bassi, J., De Marco, A., Chen, A., Walls, A. C., Di Iulio, J., Tortorici, M. A., Navarro, M.-J., Silacci-Fregni, C., Saliba, C., et al. (2021) · Science · doi:10.1126/science.abi7994 · Cited by 412
Self-citation
Mosaic nanoparticles elicit cross-reactive immune responses to zoonotic coronaviruses in mice
Cohen, A. A., Gnanapragasam, P. N. P., Lee, Y. E., Hoffman, P. R., Ou, S. K.-H., Kakutani, L. M., Keeffe, J. R., Wu, H., Howarth, M. R., West, A. P., et al. (2021) · Science · doi:10.1126/science.abf6840 · Cited by 396
Tackling COVID-19 with neutralizing monoclonal antibodies
Corti, D., Purcell, L. A., Snell, G., & Veesler, D. (2021) · Cell · doi:10.1016/j.cell.2021.05.005 · Cited by 386
Self-citation
Structural and functional ramifications of antigenic drift in recent SARS-CoV-2 variants
Yuan, M., Huang, D., Lee, C.-C. D., Wu, N. C., Jackson, A. M., Zhu, X., Liu, H., Peng, L., van Gils, M. J., Sanders, R. W., et al. (2021) · doi:10.1101/2021.02.16.430500 · Cited by 364 · cited 1×
“The K417N mutation dampens receptor recognition by about 3-fold ( 2 , 6 , 39 , 45 ) likely through loss of a salt bridge with ACE2 D30 (Fig.”
Privateer: software for the conformational validation of carbohydrate structures
Agirre, J., Iglesias‐Fernández, J., Rovira, C., Davies, G. J., Wilson, K. S., & Cowtan, K. D. (2015) · Nature Structural & Molecular Biology · doi:10.1038/nsmb.3115 · Cited by 355
Neutralizing and protective human monoclonal antibodies recognizing the N-terminal domain of the SARS-CoV-2 spike protein
Suryadevara, N., Shrihari, S., Gilchuk, P., VanBlargan, L. A., Binshtein, E., Zost, S. J., Nargi, R. S., Sutton, R. E., Winkler, E. S., Chen, E. C., et al. (2021) · Cell · doi:10.1016/j.cell.2021.03.029 · Cited by 345
Adjuvanting a subunit COVID-19 vaccine to induce protective immunity
Arunachalam, P. S., Walls, A. C., Golden, N., Atyeo, C. G., Fischinger, S., Li, C., Aye, P. P., Navarro, M. J., Lai, L., Edara, V. V., et al. (2021) · Nature · doi:10.1038/s41586-021-03530-2 · Cited by 317
Self-citation
Broad and potent activity against SARS-like viruses by an engineered human monoclonal antibody
Rappazzo, C. G., Tse, L. V., Kaku, C. I., Wrapp, D., Sakharkar, M., Huang, D., Deveau, L. M., Yockachonis, T. J., Herbert, A. S., Battles, M. B., et al. (2021) · Science · doi:10.1126/science.abf4830 · Cited by 307
An infectious SARS-CoV-2 B.1.1.529 Omicron virus escapes neutralization by therapeutic monoclonal antibodiesPreprint
VanBlargan, L., Errico, J., Halfmann, P., et al. (2021) · Research Square · doi:10.21203/rs.3.rs-1175516/v1 · Cited by 293
Genetic and structural basis for SARS-CoV-2 variant neutralization by a two-antibody cocktail
Dong, J., Zost, S. J., Greaney, A. J., Starr, T. N., Dingens, A. S., Chen, E. C., Chen, R. E., Case, J. B., Sutton, R. E., Gilchuk, P., et al. (2021) · Nature Microbiology · doi:10.1038/s41564-021-00972-2 · Cited by 285
Molecular basis of immune evasion by the Delta and Kappa SARS-CoV-2 variants
McCallum, M., Walls, A. C., Sprouse, K. R., Bowen, J. E., Rosen, L. E., Dang, H. V., Marco, A. D., Franko, N., Tilles, S. W., Logue, J. K., et al. (2021) · Science · doi:10.1126/science.abl8506 · Cited by 280 · cited 1×
“1D) ( 2 , 22 ).”
Self-citation
Broad sarbecovirus neutralization by a human monoclonal antibody
Tortorici, M. A., Czudnochowski, N., Starr, T. N., Marzi, R., Walls, A. C., Zatta, F., Bowen, J. E., Jaconi, S., di Iulio, J., Wang, Z., et al. (2021) · Nature · doi:10.1038/s41586-021-03817-4 · Cited by 255 · cited 2×
“Dampened S 1 subunit shedding might enhance the effector function activity of vaccine-or infection-elicited Abs along with that of therapeutic mAbs ( 21 ) that retain affinity for Omicron S.”
Self-citation
Broadly neutralizing antibodies overcome SARS-CoV-2 Omicron antigenic shift
Cameroni, E., Bowen, J. E., Rosen, L. E., Saliba, C., Zepeda, S. K., Culap, K., Pinto, D., VanBlargan, L. A., Marco, A. D., di Iulio, J., et al. (2021) · Nature · doi:10.1038/d41586-021-03825-4 · Cited by 251
Self-citation
Antibodies elicited by mRNA-1273 vaccination bind more broadly to the receptor binding domain than do those from SARS-CoV-2 infection
Greaney, A. J., Loes, A. N., Gentles, L. E., Crawford, K. H. D., Starr, T. N., Malone, K. D., Chu, H. Y., & Bloom, J. D. (2021) · Science Translational Medicine · doi:10.1126/scitranslmed.abi9915 · Cited by 244
Omicron escapes the majority of existing SARS-CoV-2 neutralizing antibodies
Cao, Y., Wang, J., Jian, F., Xiao, T., Song, W., Yisimayi, A., Huang, W., Li, Q., Wang, P., An, R., et al. (2021) · Nature · doi:10.1038/d41586-021-03796-6 · Cited by 227
Considerable escape of SARS-CoV-2 Omicron to antibody neutralization
Planas, D., Saunders, N., Maes, P., Guivel‐Benhassine, F., Planchais, C., Buchrieser, J., Bolland, W., Porrot, F., Staropoli, I., Lemoine, F., et al. (2021) · Nature · doi:10.1038/d41586-021-03827-2 · Cited by 194
Elicitation of broadly protective sarbecovirus immunity by receptor-binding domain nanoparticle vaccines
Walls, A. C., Miranda, M. C., Schäfer, A., Pham, M. N., Greaney, A., Arunachalam, P. S., Navarro, M.-J., Tortorici, M. A., Rogers, K., O’Connor, M. A., et al. (2021) · Cell · doi:10.1016/j.cell.2021.09.015 · Cited by 185 · cited 1×
“The identification of broadly reactive mAbs that neutralize multiple distinct sarbecoviruses, including SARS-CoV-2 variants, pave the way for designing vaccines eliciting broad sarbecovirus immunity ( 52 – 56 ).”
Self-citation
Cryo-electron microscopy structures of the N501Y SARS-CoV-2 spike protein in complex with ACE2 and 2 potent neutralizing antibodies
Zhu, X. Q., Mannar, D., Srivastava, S. S., Berezuk, A., Demers, J., Saville, J. W., Leopold, K., Li, W., Dimitrov, D. S., Tuttle, K. S., et al. (2021) · PLoS Biology · doi:10.1371/journal.pbio.3001237 · Cited by 183
Chimeric spike mRNA vaccines protect against Sarbecovirus challenge in mice
Martinez, D. R., Schäfer, A., Leist, S. R., la Cruz, G. D., West, A., Atochina‐Vasserman, E. N., Lindesmith, L. C., Pardi, N., Parks, R., Barr, M., et al. (2021) · Science · doi:10.1126/science.abi4506 · Cited by 175
Emerging SARS-CoV-2 variants expand species tropism to murines
Shuai, H., Chan, J. F., Yuen, T. T., Yoon, C., Hu, J., Wen, L., Hu, B., Yang, D., Wang, Y., Hou, Y., et al. (2021) · EBioMedicine · doi:10.1016/j.ebiom.2021.103643 · Cited by 166 · cited 1×
“Although the N501Y mutation has been described previously to enable some SARS-CoV-2 VOC to infect and replicate in mice, the Alpha and Beta variant RBDs only weakly bound mouse ACE2 ( 47 , 48 ).”
Convalescent-Phase Sera and Vaccine-Elicited Antibodies Largely Maintain Neutralizing Titer against Global SARS-CoV-2 Variant Spikes
Tada, T., Dcosta, B. M., Samanovic, M. I., Herati, R. S., Cornelius, A. R., Zhou, H., Vaill, A., Kazmierski, W., Mulligan, M. J., & Landau, N. R. (2021) · mBio · doi:10.1128/mbio.00696-21 · Cited by 155 · cited 1×
“S3, and table S3) and with previous analyses of the impact of individual mutations on neutralization by each of these two mAbs ( 9 , 38 – 40 ).”
A broadly cross-reactive antibody neutralizes and protects against sarbecovirus challenge in mice
Martinez, D. R., Schäfer, A., Gobeil, S., Li, D., la Cruz, G. D., Parks, R., Lu, X., Barr, M., Stalls, V., Janowska, K., et al. (2021) · Science Translational Medicine · doi:10.1126/scitranslmed.abj7125 · Cited by 137
Antibody-mediated broad sarbecovirus neutralization through ACE2 molecular mimicry
Park, Y., Marco, A. D., Starr, T. N., Liu, Z., Pinto, D., Walls, A. C., Zatta, F., Zepeda, S. K., Bowen, J. E., Sprouse, K. R., et al. (2022) · Science · doi:10.1126/science.abm8143 · Cited by 135
Self-citation
Track Omicron’s spread with molecular data
Scott, L. E., Hsiao, M., Moyo, S., Singh, L., Tegally, H., Dor, G., Maes, P., Pybus, O. G., Kraemer, M. U. G., Semenova, E., et al. (2021) · Science · doi:10.1126/science.abn4543 · Cited by 109
Automatically Fixing Errors in Glycoprotein Structures with Rosetta
Frenz, B., Rämisch, S., Borst, A. J., Walls, A. C., Adolf‐Bryfogle, J., Schief, W. R., Veesler, D., & DiMaio, F. (2018) · Structure · doi:10.1016/j.str.2018.09.006 · Cited by 104
Self-citation
Broad cross-reactivity across sarbecoviruses exhibited by a subset of COVID-19 donor-derived neutralizing antibodies
Jette, C. A., Cohen, A. A., Gnanapragasam, P. N. P., Muecksch, F., Lee, Y. E., Huey‐Tubman, K. E., Schmidt, F., Hatziioannou, T., Bieniasz, P. D., Nussenzweig, M. C., et al. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.109760 · Cited by 99
Neutralization and Stability of SARS-CoV-2 Omicron VariantPreprint
Zeng, C., Evans, J. P., Qu, P., Faraone, J. N., Zheng, Y.-M., Carlin, C., Bednash, J. S., Zhou, T., Lozanski, G., Mallampalli, R. K., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.12.16.472934 · Cited by 87 · cited 1×
“Putatively enhanced interactions between the S 1 and S 2 subunits in Omicron S along with pre-fusion stabilization, and altered processing at the S 1 /S 2 cleavage site due to the N679K and P681H mutations, might reduce S 1 shedding, consistent with recent studies ( 18 – 20 ).”
Infection of wild-type mice by SARS-CoV-2 B.1.351 variant indicates a possible novel cross-species transmission route
Pan, T. S., Chen, R., He, X., Yuan, Y., Deng, X., Li, R., Yan, H., Yan, S., Liu, J., Zhang, Y., et al. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00848-1 · Cited by 72 · cited 1×
“Although the N501Y mutation has been described previously to enable some SARS-CoV-2 VOC to infect and replicate in mice, the Alpha and Beta variant RBDs only weakly bound mouse ACE2 ( 47 , 48 ).”
An infectious SARS-CoV-2 B.1.1.529 Omicron virus escapes neutralization by several therapeutic monoclonal antibodies
VanBlargan, L., Errico, J., Halfmann, P., et al. (2021) · bioRxiv · doi:10.1101/2021.12.15.472828 · Cited by 59 · cited 5×
“This finding likely explains the similarly moderate reduction of S309 potency against the single G339D S mutant ( 9 ) or the full constellation of Omicron S mutations ( 7 , 9 – 11 ).”
Influential
Structure-based design of a highly stable, covalently-linked SARS-CoV-2 spike trimer with improved structural properties and immunogenicityPreprint
Olmedillas, E., Mann, C. J., Peng, W., Wang, Y.-T., Díaz-Avalos, R., Bedinger, D., Valentine, K. M., Shafee, N., Schendel, S. L., Yuan, M., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.05.06.441046 · Cited by 23
SARS-CoV-2 spike conformation determines plasma neutralizing activityPreprint
Bowen, J. E., Walls, A. C., Joshi, A., Sprouse, K. R., Stewart, C., Tortorici, M. A., Franko, N., Logue, J. K., Mazzitelli, I. G., Tilles, S. W., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.12.19.473391 · Cited by 21 · cited 1×
“The RBD is the main target of plasma neutralizing activity in convalescent and vaccinated individuals and comprises several antigenic sites recognized by neutralizing Abs with a range of neutralization potencies and breadth ( 12 , 13 , 21 , 23 – 36 ) (Fig.”
Self-citation
Attenuated fusogenicity and pathogenicity of SARS-CoV-2 Omicron variantPreprint
Sato, K., Suzuki, R., Yamasoba, D., et al. (2022) · Research Square · doi:10.21203/rs.3.rs-1207670/v1 · Cited by 9

Research works printed but not linked: 2

10.1016/j.cell.2020.02.058 · DOI · Paper page
10.1126/science.abh1139 · DOI · Paper page

Sorted by citations

The evolution of SARS-CoV-2
Markov, P. V., Ghafari, M., Beer, M., Lythgoe, K., Simmonds, P., Stilianakis, N. I., & Katzourakis, A. (2023) · Nature Reviews Microbiology · doi:10.1038/s41579-023-00878-2 · Cited by 1,179
Altered TMPRSS2 usage by SARS-CoV-2 Omicron impacts infectivity and fusogenicity
Meng, B., Abdullahi, A., Ferreira, I. A. T. M., Goonawardane, N., Saito, A., Kimura, I., Yamasoba, D., Gerber, P. P., Fatihi, S., Rathore, S., et al. (2022) · Nature · doi:10.1038/s41586-022-04474-x · Cited by 1,146
Self-citation
SARS-CoV-2 Omicron variant: Antibody evasion and cryo-EM structure of spike protein–ACE2 complex
Mannar, D., Saville, J. W., Zhu, X., Srivastava, S. S., Berezuk, A. M., Tuttle, K. S., Marquez, A. C., Sekirov, I., & Subramaniam, S. (2022) · Science · doi:10.1126/science.abn7760 · Cited by 630
SARS-CoV-2 Omicron virus causes attenuated disease in mice and hamsters
Halfmann, P., Iida, S., Iwatsuki‐Horimoto, K., Maemura, T., Kiso, M., Scheaffer, S. M., Darling, T. L., Joshi, A., Loeber, S. J., Singh, G., et al. (2022) · Nature · doi:10.1038/s41586-022-04441-6 · Cited by 664
Self-citation
Antibody escape of SARS-CoV-2 Omicron BA.4 and BA.5 from vaccine and BA.1 serum
Tuekprakhon, A., Nutalai, R., Dijokaite-Guraliuc, A., Zhou, D., Ginn, H. M., Selvaraj, M., Liu, C., Mentzer, A. J., Supasa, P., Duyvesteyn, H. M. E., et al. (2022) · Cell · doi:10.1016/j.cell.2022.06.005 · Cited by 687

See all 535

Authors: McCallum, M., Czudnochowski, N., Rosen, L. E., Zepeda, S. K., Bowen, J. E., Walls, A. C., Hauser, K., Joshi, A., Stewart, C., Dillen, J. R., Powell, A. E., Croll, T. I., Nix, J., Virgin, H. W., Corti, D., Snell, G., & Veesler, D.
Affiliations: University of Washington (US)
VIR Biotechnology (United States) (US)
Howard Hughes Medical Institute (US)
University of Cambridge (GB)
Lawrence Berkeley National Laboratory (US)
Washington University in St. Louis (US)
Vir Biotechnology (Switzerland) (CH)
Corresponding author: McCallum, Matthew
Czudnochowski, Nadine
Snell, Gyorgy
Veesler, David
ORCID: McCallum, Matthew
Czudnochowski, Nadine
Rosen, Laura E.
Zepeda, Samantha K.
Bowen, John E.
Walls, Alexandra C.
Hauser, Kevin
Stewart, Cameron
Dillen, Josh R.
Powell, Abigail E.
Croll, Tristan I.
Nix, Jay
Virgin, Herbert W.
Corti, Davide
Snell, Gyorgy
Veesler, David
Venue: Science
Publisher: American Association for the Advancement of Science (AAAS)
Published: 2022-02-25
Volume: 375
Issue: 6583
Pages: 864-868
ISSN: 0036-8075 (ISSN-L)
1095-9203
DOI: 10.1126/science.abn8652
PMC: PMC9427005
OpenAlex: W4220861013
Cited by: 535
References: 85
Citations by year: 2026: 25 · 2025: 56 · 2024: 85 · 2023: 122 · 2022: 246
FWCI: 62.11
Type: journal article
Language: en
Open access: hybrid
doi.org
Licence: cc-by
Locations: Science (publishedVersion, cc-by)
bioRxiv (Cold Spring Harbor Laboratory) (acceptedVersion, cc-by-nc-nd)
PubMed Central (publishedVersion, cc-by)
PubMed (publishedVersion)
OSTI OAI (U.S. Department of Energy Office of Scientific and Technical Information) (submittedVersion, cc-by)
eScholarship (California Digital Library) (submittedVersion)
Funders: Howard Hughes Medical Institute (DE-AC02-05CH11231)
U.S. Department of Energy (-AC02-05CH11231, Contract No. DE-AC02-05-CH11231, 05CH11231, No. DE-AC02-05-CH11231, DE AC02 05CH11231, DE-AC02-)
Burroughs Wellcome Fund (DE-AC02-05CH11231)
University of Washington
Wellcome Trust (Z/17/Z, 209407/Z/17/Z)
Fast Grants
National Institutes of Health (S10 OD032290, DE-AC02–05CH11231, 1s10od023476-01, HHSN272201700059C)
Office of Science (No. DE-AC02- 05-CH11231, DEAC02–05CH11231, AC02-05CH11231, DE-AC02, 05CH11231, Contract No. DE-AC02-05CH11231)
National Institute of General Medical Sciences (DE-AC02-05CH11231, R01GM120553, T32GM008268, P30GM124169)
National Institute of Allergy and Infectious Diseases (HHSN272201700059C, DP1AI158186)
Topics: Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › vaccines and immunoinformatics approaches
Life Sciences › Agricultural and Biological Sciences › Animal Science and Zoology › Animal Virus Infections Studies
Keywords: Omicron variant, spike protein, receptor binding domain, antibody escape, sotrovimab, ACE2 receptor, antigenic shift, spike protein mutations, antibody affinity
MeSH terms: Protein Domains, Broadly Neutralizing Antibodies, Receptors, Coronavirus, Angiotensin-Converting Enzyme 2, SARS-CoV-2, Antigenic Drift and Shift, Antibodies, Monoclonal, Antibodies, Viral, Humans, Models, Molecular, Mutation, Protein Binding, Protein Conformation, Crystallography, X-Ray, Amino Acid Substitution, Cryoelectron Microscopy, Protein Interaction Domains and Motifs, Immune Evasion, Spike Glycoprotein, Coronavirus

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Structural basis of SARS-CoV-2 Omicron immune evasion and receptor engagement

Abstract

Overview

Integrity signals

Figures

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks